PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

News & events

Press release
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

Webinar being held today “Evolving strategic context for phages, Introducing new opportunities” to present PHAXIAM Therapeutics strategy

Read more
Press release
PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first “Phagogram Day”

organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scale

Read more
Press release
PHAXIAM Reports Third-Quarter 2024 Financial Information

Cash and cash equivalents of €5.7 million as of September 30, 2024

Read more
Press release
PHAXIAM Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

PHAXIAM has received Investigational New Drug approval (IND) for its Phase II study, GLORIA, in Prosthetic Joint Infections (PJI) caused by Staphylococcus aureus (S. aureus). 

Read more
Press release
PHAXIAM announces the validation of a new investigator-initiated phase 2 study, PHAGOSCARPA, in the treatment of extra-cavitary vascular grafts implant infection caused by Staphylococcus aureus in which the company will be involved

Sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)

Read more
Press release
PHAXIAM Provides Business and Financial Update For the First Half of 2024

Webinar (in French) today, September 25, 2024 at 6:00 pm CEST Click here to attend

Read more
Press release
Share capital increase : Result Press release

Read more
Press release
Share capital increase : Launch Press release

Read more
Press release
RESULTS OF THE COMBINED GENERAL MEETING OF 28 JUNE 2024

The shareholders approved all the resolutions on which the Board of Directors recommended a favorable vote

Read more
Press release
PHAXIAM Therapeutics announces the success of its rights issue of €7.8m

Following the subscription period, which closed on June 25, 2024, total demand amounted to approximately 3.9 million shares, representing approximately €7.8 million, i.e. a subscription rate of around 77.1%:

Read more
Press release
PHAXIAM Therapeutics launches a rights issue of approximately €10m, which may be increased up to approximately €11.5m if the extension clause is exercised in full, in order to accelerate the implementation of its clinical strategy

Webinar (in French) on June 18, 2024, at 6:00 pm : Register here

Read more
Press release
PHAXIAM announces the availability of the preparatory documents  for the Combined General Meeting of 28 June 2024

Shareholders of PHAXIAM are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company’s registered office at 60 avenue Rockefeller – 69008 Lyon (France).

Read more

Contact
our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us